Dana Carroll

Dana Carroll, PhD

Languages spoken: English

Academic Information

Departments Primary - Biochemistry

Lab

Dana Carroll, PhD, is a Distinguished Professor in the Department of Biochemistry at the University of Utah School of Medicine.

Carroll’s research involves genome engineering using targetable nucleases. His lab pioneered the development of zinc-finger nucleases as gene targeting tools and continued working with the more recent TALENs and CRISPR/Cas nucleases. Much of the effort was focused on optimizing the efficiency of these reagents for targeted mutagenesis and gene replacement, which could ultimately provide treatment for many diseases, including certain types of cancer. This technology has now been applied to more than 200 different organisms, including current clinical trials in humans and improvements in crop plants and livestock. Carroll no longer has an active research laboratory, but he maintains an interest in the applications and societal implications of genome editing.

Carroll received his bachelor’s degree from Swarthmore College, Pennsylvania, and his PhD from the University of California, Berkeley. He did postdoctoral research at the Beatson Institute for Cancer Research in Glasgow, Scotland, and at the Carnegie Institution of Washington Department of Embryology in Baltimore.

Education History

Undergraduate Swarthmore College
 BA
Doctoral Training University of California, Berkeley
 PhD
Postdoctoral Fellowship Beatson Institute for Cancer Research
 Postdoctoral Fellow
Postdoctoral Fellowship Carnegie Institution of Washington
 Postdoctoral Fellow

Selected Publications

Journal Article

  1. Cho SW, Lee J, Carroll D, Kim JS, Lee (2013). Heritable gene knockout in Caenorhabditis elegans by direct injection of Cas9-sgRNA ribonucleoproteins. Genetics, 195(3), 1177-80. (Read full article)
  2. Sarno R, Vicq Y, Uematsu N, Luka M, Lapierre C, Carroll D, Bastianelli G, Serero A, Nicolas (2017). Programming sites of meiotic crossovers using Spo11 fusion proteins. Nucleic acids research, 45(19), e164. (Read full article)
  3. Yarrington RM, Verma S, Schwartz S, Trautman JK, Carroll (2018). Nucleosomes inhibit target cleavage by CRISPR-Cas9 in vivo.LID - 201810062 [pii]LID - 10.1073/pnas.1810062115 [doi]. Proceedings of the National Academy of Sciences of the United States of America, 115, 9351-9358. (Read full article)
  4. Beumer KJ, Carroll (2014). Targeted genome engineering techniques in Drosophila. Methods (San Diego, Calif.), 68(1), 29-37. (Read full article)
  5. Carroll D, Beumer K (2014). Genome engineering with TALENs and ZFNs: repair pathways and donor design. Methods (San Diego, Calif.), 69(2), 137-41. (Read full article)
  6. DeWitt MA, Corn JE, Carroll (2017). Genome editing via delivery of Cas9 ribonucleoprotein. Methods (San Diego, Calif.), 121-122, 9-15. (Read full article)
  7. DeWitt MA, Magis W, Bray NL, Wang T, Berman JR, Urbinati F, Heo SJ, Mitros T, Munoz DP, Boffelli D, Kohn DB, Walters MC, Carroll D, Martin DI, Corn J (2016). Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Science translational medicine, 8(360), 360ra134. (Read full article)
  8. Beumer KJ, Trautman JK, Mukherjee K, Carroll (2013). Donor DNA Utilization during Gene Targeting with Zinc-finger Nucleases.LID - g3.112.005439v2 [pii]LID - 10.1534/g3.112.005439 [doi]. G3 (Bethesda, Md.), 3, 657-664. (Read full article)
  9. Beumer KJ, Trautman JK, Christian M, Dahlem TJ, Lake CM, Hawley RS, Grunwald DJ, Voytas DF, Carroll (2013). Comparing zinc finger nucleases and transcription activator-like effector nucleases for gene targeting in Drosophila. G3 (Bethesda, Md.), 3(10), 1717-25. (Read full article)
  10. Wilson RC, Carroll (2019). The Daunting Economics of Therapeutic Genome Editing. CRISPR J, 2(5), 280-284. (Read full article)
  11. Christensen S, Pont-Kingdon G, Carroll (2000). Target specificity of the endonuclease from the Xenopus laevis non-long terminal repeat retrotransposon, Tx1L. Molecular and cellular biology, 20(4), 1219-26. (Read full article)
  12. Bibikova M, Wu B, Chi E, Kim KH, Trautman JK, Carroll (1998). Characterization of FEN-1 from Xenopus laevis. cDNA cloning and role in DNA metabolism. The Journal of biological chemistry, 273(51), 34222-9. (Read full article)
  13. Segal DJ, Faruqi AF, Glazer PM, Carroll (1997). Processing of targeted psoralen cross-links in Xenopus oocytes. Molecular and cellular biology, 17(11), 6645-52. (Read full article)
  14. Pont-Kingdon G, Chi E, Christensen S, Carroll (1997). Ribonucleoprotein formation by the ORF1 protein of the non-LTR retrotransposon Tx1L in Xenopus oocytes. Nucleic acids research, 25(15), 3088-94. (Read full article)
  15. Segal DJ, Carroll (1995). Endonuclease-induced, targeted homologous extrachromosomal recombination in Xenopus oocytes. Proceedings of the National Academy of Sciences of the United States of America, 92(3), 806-10. (Read full article)
  16. Lehman CW, Jeong-Yu S, Trautman JK, Carroll (1994). Repair of heteroduplex DNA in Xenopus laevis oocytes. Genetics, 138(2), 459-70. (Read full article)
  17. Carroll D, Lehman CW, Jeong-Yu S, Dohrmann P, Dawson RJ, Trautman J (1994). Distribution of exchanges upon homologous recombination of exogenous DNA in Xenopus laevis oocytes. Genetics, 138(2), 445-57. (Read full article)
  18. Lehman CW, Trautman JK, Carroll (1994). Illegitimate recombination in Xenopus: characterization of end-joined junctions. Nucleic acids research, 22(3), 434-42. (Read full article)
  19. Lehman CW, Clemens M, Worthylake DK, Trautman JK, Carroll (1993). Homologous and illegitimate recombination in developing Xenopus oocytes and eggs. Molecular and cellular biology, 13(11), 6897-906. (Read full article)
  20. Lehman CW, Carroll (1993). Isolation of large quantities of functional, cytoplasm-free Xenopus laevis oocyte nuclei. Analytical biochemistry, 211(2), 311-9. (Read full article)
  21. Jeong-Yu S, Carroll (1992). Effect of terminal nonhomologies on homologous recombination in Xenopus laevis oocytes. Molecular and cellular biology, 12(12), 5426-37. (Read full article)
  22. Lehman CW, Carroll (1991). Homologous recombination catalyzed by a nuclear extract from Xenopus oocytes. Proceedings of the National Academy of Sciences of the United States of America, 88(23), 10840-4. (Read full article)
  23. Maryon E, Carroll (1991). Characterization of recombination intermediates from DNA injected into Xenopus laevis oocytes: evidence for a nonconservative mechanism of homologous recombination. Molecular and cellular biology, 11(6), 3278-87. (Read full article)
  24. Maryon E, Carroll (1991). Involvement of single-stranded tails in homologous recombination of DNA injected into Xenopus laevis oocyte nuclei. Molecular and cellular biology, 11(6), 3268-77. (Read full article)
  25. Carroll D, Lehman C (1991). DNA recombination and repair in oocytes, eggs, and extracts. Methods in cell biology, 36, 467-86. (Read full article)
  26. Urnes MS, Carroll (1990). Amylase synthesis as a simple model system for translation and hybrid arrest in Xenopus oocytes. Gene, 95(2), 267-74. (Read full article)
  27. Sweigert SE, Carroll (1990). Repair and recombination of X-irradiated plasmids in Xenopus laevis oocytes. Molecular and cellular biology, 10(11), 5849-56. (Read full article)
  28. Maryon E, Carroll (1989). Degradation of linear DNA by a strand-specific exonuclease activity in Xenopus laevis oocytes. Molecular and cellular biology, 9(11), 4862-71. (Read full article)
  29. Garrett JE, Knutzon DS, Carroll (1989). Composite transposable elements in the Xenopus laevis genome. Molecular and cellular biology, 9(7), 3018-27. (Read full article)

Review

  1. Carroll (2014). Genome engineering with targetable nucleases. Annual review of biochemistry, 83, 409-39. (Read full article)
  2. Carroll (2015). Genome editing by targeted chromosomal mutagenesis. Methods in molecular biology (Clifton, N.J.), 1239, 1-13. (Read full article)
  3. Chandrasegaran S, Carroll (2015). Origins of Programmable Nucleases for Genome Engineering.LID - S0022-2836(15)00606-3 [pii]LID - 10.1016/j.jmb.2015.10.014 [doi]. Journal of molecular biology, 428, 963-89. (Read full article)
  4. Carroll (2017). Genome Editing: Past, Present, and Future. The Yale journal of biology and medicine, 90(4), 653-659. (Read full article)
  5. Carroll D, Charo R (2015). The societal opportunities and challenges of genome editing. Genome biology, 16(1), 242. (Read full article)
  6. Pauwels K, Podevin N, Breyer D, Carroll D, Herman (2014). Engineering nucleases for gene targeting: safety and regulatory considerations. New biotechnology, 31(1), 18-27. (Read full article)
  7. Carroll (2023). RNA in Therapeutics: CRISPR in the Clinic. Molecules and cells, 46(1), 4-9. (Read full article)
  8. Carroll (2021). A short, idiosyncratic history of genome editing. Gene and genome editing, 1, 100002.

Commentary

  1. Chandrasegaran S, Bullen CK, Carroll (2017). Genome editing of human embryos: to edit or not to edit, that is the question. The Journal of clinical investigation, 127(10), 3588-3590. (Read full article)
  2. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, Greely HT, Jinek M, Martin GS, Penhoet E, Puck J, Sternberg SH, Weissman JS, Yamamoto K (2015). Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science (New York, N.Y.), 348(6230), 36-8. (Read full article)
  3. Carroll (2018). p53 Throws CRISPR a Curve. Trends in pharmacological sciences, 39(9), 783-784. (Read full article)
  4. Carroll (2014). Precision genome engineering. Current biology, 24(3), R102-3. (Read full article)
  5. Carroll (2013). Staying on target with CRISPR-Cas. Nature biotechnology, 31(9), 807-9. (Read full article)
  6. Bosley KS, Botchan M, Bredenoord AL, Carroll D, Charo RA, Charpentier E, Cohen R, Corn J, Doudna J, Feng G, Greely HT, Isasi R, Ji W, Kim JS, Knoppers B, Lanphier E, Li J, Lovell-Badge R, Martin GS, Moreno J, Naldini L, Pera M, Perry AC, Venter JC, Zhang F, Zhou (2015). CRISPR germline engineering--the community speaks. Nature biotechnology, 33(5), 478-86. (Read full article)
  7. Carroll (2012). A CRISPR approach to gene targeting. Molecular therapy, 20(9), 1658-60. (Read full article)
  8. Carroll (2016). A Perspective on the State of Genome Editing. Molecular therapy, 24(3), 412-3. (Read full article)
  9. Carroll (2016). Genome editing: progress and challenges for medical applications. Genome medicine, 8(1), 120. (Read full article)
  10. Carroll (2022). Rewriting Nature: The case of heritable human genome editing. Boston University Law Review Online, 102, 1-6.
  11. Carroll D, Meyer B (2021). Life 2.0 - A CRISPR approach to a sustainable planet. Proceedings of the National Academy of Sciences of the United States of America, 118(22), e2107418118.

Editorial

  1. Carroll (2019). Collateral damage: benchmarking off-target effects in genome editing. Genome biology, 20(1), 114. (Read full article)

Letter

  1. Carroll D, Van Eenennaam AL, Taylor JF, Seger J, Voytas D (2016). Regulate genome-edited products, not genome editing itself. Nature biotechnology, 34(5), 477-9. (Read full article)
  2. Urnov FD, Ronald PC, Carroll (2018). A call for science-based review of the European court's decision on gene-edited crops. Nature biotechnology, 36(9), 800-802. (Read full article)
  3. Hackett P, Carroll (2015). Regulatory hurdles for agriculture GMOs. Science (New York, N.Y.), 347(6228), 1324. (Read full article)